Board Change • May 21
High number of new and inexperienced directors There are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 1 experienced director. No highly experienced directors. Independent Non-Executive Chairman Gilbert Ghostine is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Annonce • May 16
Sandoz Group AG Confirms European Commission Approval for Biosimilars Bysumlog® (Insulin Lispro) and Dazparda® (Insulin Aspart), Strengthening Position in Diabetes Sandoz Group AG confirms that the European Commission has granted marketing authorisation for Bysumlog (insulin lispro) and Dazparda (insulin aspart). The two biosimilar insulins, for injection in prefilled pens, are developed by Gan & Lee Pharmaceuticals. Bysumlog is approved for the treatment and initial stabilisation of diabetes mellitus in adults and children1, while Dazparda is approved for the treatment of diabetes mellitus in adults, adolescents and children aged one year or more . Both biosimilar insulins have equivalent efficacy and comparable safety to their respective reference medicines, Humalog® and NovoRapid® . Following these approvals, Bysumlog and Dazparda have the potential to increase competition, improve affordability and expand access to insulin treatment options for millions of people living with diabetes across Europe. Diabetes is a chronic condition that occurs when either the pancreas does not produce enough insulin, a hormone that regulates blood glucose, or when the body cannot effectively use the insulin it produces. The disease and its complications can cause blindness, kidney failure, heart attacks, stroke and lower-limb amputation in some patients . An estimated 66 million adults aged 20–79 in Europe live with diabetes and this is projected to rise by 10% to 72 million by 2050, with related healthcare expenditure approaching USD 200 billion . Sandoz entered into an agreement with Gan & Lee in December 2018 to commercialise biosimilar versions of the insulins aspart, lispro and glargine. Under the terms of the agreement, Sandoz will commercialise in Europe and other key territories around the world, while Gan & Lee is responsible for development, manufacturing and supply. The approvals contribute to the continued Sandoz leadership and pioneering legacy in biosimilars, dating back to the introduction of the first biosimilar in 2006. They underscore the company’s commitment to help millions of patients access biologic medicines sustainably and affordably through a global portfolio of 13 biosimilars, supported by an industry-leading pipeline. They further strengthen the Sandoz position in diabetes, while representing another step towards the overall strategic objective of capitalising on a projected approximately USD 320 billion biosimilar market opportunity over the next 10 years . Board Change • May 05
High number of new and inexperienced directors There are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 1 experienced director. No highly experienced directors. Independent Non-Executive Chairman Gilbert Ghostine is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Annonce • Mar 09
Sandoz Group AG, Annual General Meeting, Apr 09, 2026 Sandoz Group AG, Annual General Meeting, Apr 09, 2026, at 10:00 W. Europe Standard Time. New Risk • Mar 04
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Austrian stocks, typically moving 4.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Reported Earnings • Feb 28
Full year 2025 earnings released Full year 2025 results: EPS: US$2.12. Revenue: US$11.2b (up 7.4% from FY 2024). Net income: US$914.0m (up US$914.0m from FY 2024). Profit margin: 8.2% (up from 0% in FY 2024). The increase in margin was primarily driven by higher revenue. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Pharmaceuticals industry in Europe. Annonce • Feb 27
Sandoz Group AG announces Annual dividend, payable on April 15, 2026 Sandoz Group AG announced Annual dividend of CHF 0.8000 per share payable on April 15, 2026, ex-date on April 13, 2026 and record date on April 14, 2026. Annonce • Feb 26
Sandoz Confirms European Commission Approval for Ranluspec®? (Ranibizumab) Sandoz confirmed that the European Commission has granted marketing authorization for Ranluspec. Ranluspec is developed, manufactured and registered by Lupin and was approved based on the review of a comprehensive data package. Ranluspec is indicated for the treatment of neovascular (wet) age-related macular degeneration (nAMD), visual impairment due to diabetic macular edema, proliferative diabetic retinopathy, visual impairment due to macular edema secondary to retinal vein occlusion and visual impairment due to choroidal neovascularization. Ranluspec has equivalent efficacy and comparable safety to its reference medicine, Lucentis®?. Around four million people are estimated to have neovascular age-related macular degenerization in France, Germany, Italy, Spain, the UK, the US and Japan3, and between 20% and 35% of people with diabetes in Europe will develop diabetic retinopathy4. The approval paves the way for an expected launch of Ranluspec in the second half of 2026. The announcement builds on the continuing leadership and pioneering legacy Sandoz has established in biosimilars, which began with the introduction of the first biosimilar, Omnitrope®? (somatropin), in 2006. It strengthens the company's position in ophthalmology, following the launch of Afqlir®? (aflibercept) in Europe in 2025 and also represents another step towards the overall Sandoz strategic objective of capitalizing on a projected USD 320 billion biosimilar-market opportunity over the next 10 years. Sandoz and Lupin announced a commercial partnership in August 2025 for the development and commercialization of a ranibizumab biosimilar. Under the terms of the agreement, Sandoz holds exclusive commercialization rights for Ranluspec across the European Union, excluding Germany, and semi-exclusive rights in France. Sandoz is commercializing Epruvy®? (ranibizumab) in Germany under a separate agreement. Lucentis®? is a registered trademark of Genentech Inc. Annonce • Feb 21
Sandoz Group AG Receives US FDA Approval to Expand Enzeevu (Aflibercept-Abzv) Label for Multiple Retinal Indications Sandoz Group AG on February 18, 2026 announced that the US Food and Drug Administration (FDA) has approved an expanded label for Enzeevu (aflibercept-abzv), to include multiple retinal indications. Enzeevu was originally approved by the FDA for the treatment of neovascular (wet) age-related macular degeneration (nAMD) in August 2024. The most recent approval expands the Enzeevu label indications to include macular edema following retinal vein occlusion (RVO), diabetic retinopathy (DR) and diabetic macular edema (DME), along with the previously approved indication of nAMD. This expansion offers retina specialists a clinically-proven aflibercept biosimilar option to treat more patients across these retinal diseases. Sandoz is committed to helping millions of patients access critical and potentially life-changing biologic medicines sustainably and affordably, with a leading global portfolio comprising 13 biosimilars and a further 27 assets in various stages of development. This approval strengthens the company’s position in ophthalmology, following the acquisition of the US biosimilar Cimerli (ranibizumab-eqrn) in 2024 and the European launch of Afqlir (aflibercept) in 2025. It also represents another step towards the overall strategic objective of capitalizing on a projected approx. USD 320 billion biosimilar market opportunity over the next 10 years . Enzeevu is expected to launch in the US in the fourth quarter of 2026, or earlier under certain circumstances. Board Change • Feb 05
High number of new and inexperienced directors There are 10 new directors who have joined the board in the last 3 years. The company's board is composed of: 10 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Chairman Gilbert Ghostine is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Annonce • Jan 16
Sandoz Confirms European Commission Approval of Ondibta® (Insulin Glargine) Sandoz confirmed that the European Commission has granted marketing authorization for Ondibta® (insulin glargine), a solution for injection in a pre-filled pen developed and registered by Gan & Lee Pharmaceuticals. Ondibta® is approved for the treatment of diabetes mellitus in adults, adolescents and children aged two years and above and is confirmed to match the reference medicine, Lantus® SoloStar® insulin pen, in terms of safety, quality and efficacy. The approval paves the way for an expected launch of Ondibta® by early 2027, which has the potential to increase competition, improve affordability and enhance access to insulin treatment options for people living with diabetes in Europe. Diabetes is a chronic disease that occurs either when the pancreas does not produce enough insulin, a hormone that regulates blood glucose, or when the body cannot effectively use the insulin that it produces. It can cause blindness, kidney failure, heart attacks, stroke and lower limb amputation. According to latest estimates, there are 66 million adults aged 20-79 living with diabetes in Europe, a figure that is expected to increase 10% by 2050 to 72 million, with related healthcare expenditure approaching USD 200 billion. Sandoz entered into an agreement with Gan & Lee in December 2018 to commercialize biosimilar versions of the insulins glargine, lispro and aspart. Under the terms of the agreement, Sandoz will commercialize in Europe and other key territories around the world, while Gan & Lee is responsible for development, registration, manufacturing and supply. The approval builds on the continuing Sandoz leadership and pioneering legacy in biosimilars, dating back to the introduction of the first biosimilar in 2006. It also strengthens the Sandoz position in diabetes, while representing another step towards the overall strategic objective of capitalizing on a projected USD 320 billion biosimilar-market opportunity over the next 10 years. Sandoz is committed to helping millions of patients access critical and potentially life-changing biologic medicines sustainably and affordably, with a leading global portfolio comprising 13 biosimilars and a further 27 assets in various stages of development. Board Change • Jan 07
High number of new and inexperienced directors There are 10 new directors who have joined the board in the last 3 years. The company's board is composed of: 10 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Chairman Gilbert Ghostine is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Board Change • Dec 15
High number of new and inexperienced directors There are 10 new directors who have joined the board in the last 3 years. The company's board is composed of: 10 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Chairman Gilbert Ghostine is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Annonce • Dec 03
Sandoz Launches Denosumab Biosimilars in Europe, Providing Affordable Treatment Option for Cancer-Related Bone Disease and Osteoporosis for Millions of Patients Sandoz announced the European launch of Wyost ® (denosumab 120 mg) and Jubbonti ® (denosumab 60 mg). The medicines are among the first denosumab biosimilars to launch in Europe and are approved by the European Commission to treat all indications of the reference medicines, Xgeva ® (denosumab 120 mg) and Prolia (denosumab 60 mg). Wyost ® is approved for the treatment of cancer-related bone disease and Jubbonti ® is approved to treat osteoporosis. Wyost ® and Jubbonti ® represent key value drivers for Sandoz and the European launch marks the next major step in advancing the company’s growth strategy. It builds on other key biosimilar launches this year including Wyost ® and Jubbonti ® in the US and the recent launches of Tyruko ® (natalizumab) in the US and Afqlir ® (aflibercept) in Europe. Close to one quarter (4.14 million) of all newly reported cancer cases globally occur in Europe and cancer remains a leading cause of premature death for people aged 30-69 years in most European countries. Nearly all types of cancer can spread to the bone and cause pain and fractures, but cancers that often metastasize there include breast, lung and prostate Wyost ® and Jubbonti ® will be launched across Europe today, with additional rollouts to follow throughout 2026. This launch builds on the continuing Sandoz leadership and pioneering legacy in biosimilars, dating back to the introduction of the first biosimilar in 2006. It further expands the company’s presence in a global reference-medicine market worth a combined ~USD 6.6 billion and reinforces its established position in oncology and immunology. Sandoz is committed to helping millions of patients access critical and potentially life-changing biologic medicines sustainably and affordably, with a leading global portfolio comprising 13 biosimilars and a further 27 assets in various stages of development. Wyost ® (denosumab 120 mg) and Jubbonti ® (denosumab 60 mg) have been developed as biosimilars to the reference medicines Xgeva and Prolia, respectively. Both medicines contain the same active ingredient (denosumab), a human monoclonal antibody (IgG2) that targets and binds with high affinity and specificity to RANKL, preventing activation of its receptor, RANK, on the surface of osteoclast precursors and osteoclasts. Prevention of the RANKL/RANK interaction inhibits osteoclast formation, function and survival, thereby decreasing bone resorption in cortical and trabecular bone. Wyost ® is indicated in Europe to prevent skeletal related events (SREs; pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone, and to treat adults and skeletally mature adolescents with a giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity. Jubbonti ® is indicated in Europe to treat osteoporosis in postmenopausal women and in men at increased risk of fractures, bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures and bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture. Annonce • Nov 25
Sandoz Group AG Launches Afqlir®? (aflibercept) in Europe, Providing Affordable Treatment Option for Patients with Retinal Diseases Sandoz Group AG announced the European launch of Afqlir ® (aflibercept). Afqlir ®, a 2 mg vial kit and pre-filled syringe for intravitreal injection, was approved by the European Commission in November 2024 for the same indications in adult patients as the reference medicine, Eylea ®, namely the treatment of various retinal diseases to prevent disease-related blindness. Studies confirm that Afqlir ® matches the reference medicine in efficacy, safety and pharmacokinetics. Aflibercept is considered a gold standard for treating various neovascular retinal diseases. Conditions like age-related macular degeneration (AMD), retinal vein occlusion (RVO) and diabetic macular edema (DME) are leading causes of vision loss and their global prevalence is increasing. A subtype of age-related macular degeneration (AMD), nAMD is characterized by vision loss in the central zone and is a leading cause of vision impairment in patients over 65 years of age. Although nAMD represents about 10 to 20 percent of all AMD cases, it accounts for 90 percent of severe vision loss linked to AMD. In France, Germany, Italy, Spain, the UK, the US and Japan, around 4.0 million people are estimated to have nAMD. Of these, 2.8 million are diagnosed but only 2.0 million receive treatment. Afqlir ® will be launched across Europe, beginning in the UK, followed by other major markets such as Germany and France, with additional rollouts to follow in 2026. Afqlir ® is one of several biosimilar value drivers for Sandoz and this launch represents another step in advancing the company’s growth strategy, building on major launches this year including Tyruko ® (natalizumab) and Wyost ® (denosumab) and Jubbonti ® (denosumab) in the US. Sandoz is committed to helping million of patients access critical and potentially life-changing biologic medicines sustainably and affordably, with a leading global portfolio comprising 13 biosimilars and a further 27 assets in various stages of development. The launch builds on the existing Sandoz leadership and legacy in biosimilars, dating back to the introduction of the first biosimilar in 2006, and expands the company’s presence in the ~USD 15 billion anti-VEGF ophthalmology market. In September 2025, Sandoz also announced that it had reached an agreement with Regeneron Pharmaceuticals Inc. to resolve all patent disputes between the two companies relating to the US Food and Drug Administration (FDA)-approved aflibercept biosimilar, clearing the path for the launch of Enzeevu™ (aflibercept-abzv) in the US by the end of 2026. Annonce • Nov 16
Sandoz Group AG to Report First Half, 2026 Results on Aug 05, 2026 Sandoz Group AG announced that they will report first half, 2026 results on Aug 05, 2026 Board Change • Oct 30
High number of new and inexperienced directors There are 10 new directors who have joined the board in the last 3 years. The company's board is composed of: 10 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Chairman Gilbert Ghostine is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. 
